Investor's Calendar
Last News
ROVI closes the quarter with operating revenue of 151.2 million euros
4 min
08 May, 2024
Agreement to manufacture pre-filled syringes for a global pharmaceutical company
3 min
25 Apr, 2024
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the...
4 min
02 Apr, 2024
Public statements sent to CNMV
ESG
Discover what ROVI is doing to become a more sustainable company
CORPORATE GOVERNANCE
Find out more about ROVI’s main governing bodies